Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial.
Adolescents
Diabetes
Dietary fiber
Gut microbiome
Insulin resistance
Metformin
Obesity
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
17 Feb 2021
17 Feb 2021
Historique:
received:
18
11
2020
accepted:
20
01
2021
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Accumulating evidence suggests that the metabolic effects of metformin and fermentable fibers are mediated, in part, through diverging or overlapping effects on the composition and metabolic functions of the gut microbiome. Pre-clinical animal models have established that the addition of fiber to metformin monotherapy improves glucose tolerance. However, possible synergistic effects of combination therapy (metformin plus fiber) have not been investigated in humans. Moreover, the underlying mechanisms of synergy have yet to be elucidated. The aim of this study is to compare in adolescents with obesity the metabolic effects of metformin and fermentable fibers in combination with those of metformin or fiber alone. We will also determine if therapeutic responses correlate with compositional and functional features of the gut microbiome. This is a parallel three-armed, double-blinded, randomized controlled trial. Adolescents (aged 12-18 years) with obesity, insulin resistance (IR), and a family history of type 2 diabetes mellitus (T2DM) will receive either metformin (850 mg p.o. twice/day), fermentable fibers (35 g/day), or a combination of metformin plus fiber for 12 months. Participants will be seen at baseline, 3, 6, and 12 months, with a phone follow-up at 1 and 9 months. Primary and secondary outcomes will be assessed at baseline, 6, and 12 months. The primary outcome is change in IR estimated by homeostatic model assessment of IR; key secondary outcomes include changes in the Matsuda index, oral disposition index, body mass index z-score, and fat mass to fat-free mass ratio. To gain mechanistic insight, endpoints that reflect host-microbiota interactions will also be assessed: obesity-related immune, metabolic, and satiety markers; humoral metabolites; and fecal microbiota composition, short-chain fatty acids, and bile acids. This study will compare the potential metabolic benefits of fiber with those of metformin in adolescents with obesity, determine if metformin and fiber act synergistically to improve IR, and elucidate whether the metabolic benefits of metformin and fiber associate with changes in fecal microbiota composition and the output of health-related metabolites. This study will provide insight into the potential role of the gut microbiome as a target for enhancing the therapeutic efficacy of emerging treatments for T2DM prevention. ClinicalTrials.gov NCT04578652 . Registered on 8 October 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Accumulating evidence suggests that the metabolic effects of metformin and fermentable fibers are mediated, in part, through diverging or overlapping effects on the composition and metabolic functions of the gut microbiome. Pre-clinical animal models have established that the addition of fiber to metformin monotherapy improves glucose tolerance. However, possible synergistic effects of combination therapy (metformin plus fiber) have not been investigated in humans. Moreover, the underlying mechanisms of synergy have yet to be elucidated. The aim of this study is to compare in adolescents with obesity the metabolic effects of metformin and fermentable fibers in combination with those of metformin or fiber alone. We will also determine if therapeutic responses correlate with compositional and functional features of the gut microbiome.
METHODS
METHODS
This is a parallel three-armed, double-blinded, randomized controlled trial. Adolescents (aged 12-18 years) with obesity, insulin resistance (IR), and a family history of type 2 diabetes mellitus (T2DM) will receive either metformin (850 mg p.o. twice/day), fermentable fibers (35 g/day), or a combination of metformin plus fiber for 12 months. Participants will be seen at baseline, 3, 6, and 12 months, with a phone follow-up at 1 and 9 months. Primary and secondary outcomes will be assessed at baseline, 6, and 12 months. The primary outcome is change in IR estimated by homeostatic model assessment of IR; key secondary outcomes include changes in the Matsuda index, oral disposition index, body mass index z-score, and fat mass to fat-free mass ratio. To gain mechanistic insight, endpoints that reflect host-microbiota interactions will also be assessed: obesity-related immune, metabolic, and satiety markers; humoral metabolites; and fecal microbiota composition, short-chain fatty acids, and bile acids.
DISCUSSION
CONCLUSIONS
This study will compare the potential metabolic benefits of fiber with those of metformin in adolescents with obesity, determine if metformin and fiber act synergistically to improve IR, and elucidate whether the metabolic benefits of metformin and fiber associate with changes in fecal microbiota composition and the output of health-related metabolites. This study will provide insight into the potential role of the gut microbiome as a target for enhancing the therapeutic efficacy of emerging treatments for T2DM prevention.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04578652 . Registered on 8 October 2020.
Identifiants
pubmed: 33596993
doi: 10.1186/s13063-021-05060-8
pii: 10.1186/s13063-021-05060-8
pmc: PMC7890810
doi:
Substances chimiques
Hypoglycemic Agents
0
Metformin
9100L32L2N
Banques de données
ClinicalTrials.gov
['NCT04578652']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
148Références
Diabetologia. 2018 Apr;61(4):810-820
pubmed: 29379988
Curr Diab Rep. 2018 May 8;18(6):36
pubmed: 29737424
Cell. 2014 Jan 16;156(1-2):84-96
pubmed: 24412651
J Allergy Clin Immunol. 2018 Aug;142(2):424-434.e10
pubmed: 29241587
J Endocrinol. 2014 Feb 10;220(3):361-73
pubmed: 24389593
Genes (Basel). 2020 Aug 07;11(8):
pubmed: 32784572
JAMA Pediatr. 2018 Apr 1;172(4):368-377
pubmed: 29459942
Diabetes Care. 2000 Jan;23(1):57-63
pubmed: 10857969
Science. 2013 Sep 6;341(6150):1241214
pubmed: 24009397
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Pediatrics. 2001 Apr;107(4):E55
pubmed: 11335776
Pediatrics. 2015 Jan;135(1):86-93
pubmed: 25535262
Nutr Metab Cardiovasc Dis. 2016 Sep;26(9):842-7
pubmed: 27381990
Nutrients. 2017 May 20;9(5):
pubmed: 28531113
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):984-996
pubmed: 31696832
Am J Med. 2013 Dec;126(12):1059-67.e1-4
pubmed: 24135514
Microbiome. 2016 Jun 29;4(1):33
pubmed: 27357127
Pediatrics. 2005 Apr;115(4):e500-3
pubmed: 15741351
Nat Med. 2019 Jul;25(7):1096-1103
pubmed: 31263284
Curr Opin Microbiol. 2017 Aug;38:59-65
pubmed: 28486162
Cell Res. 2020 Jun;30(6):492-506
pubmed: 32433595
Gut. 2016 Mar;65(3):426-36
pubmed: 26100928
Diabetes Care. 2007 Jul;30(7):1845-50
pubmed: 17475938
Front Microbiol. 2018 Jun 05;9:1210
pubmed: 29922272
Cell Host Microbe. 2020 Mar 11;27(3):389-404.e6
pubmed: 32004499
Lancet. 2019 Feb 2;393(10170):434-445
pubmed: 30638909
Diabetes Care. 2014 Dec;37(12):3336-44
pubmed: 25414389
J Pediatr. 2011 Sep;159(3):437-441.e1
pubmed: 21489557
J Pediatr Gastroenterol Nutr. 2008 Nov;47(5):592-7
pubmed: 18979582
Nat Biotechnol. 2017 Nov;35(11):1069-1076
pubmed: 28967887
J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61
pubmed: 26900641
Pediatr Diabetes. 2007 Apr;8(2):74-87
pubmed: 17448130
Int J Obes (Lond). 2015 Mar;39(3):424-9
pubmed: 25109781
J Pediatr. 2004 Jan;144(1):47-55
pubmed: 14722518
Int J Obes (Lond). 2016 Oct;40(10):1494-1502
pubmed: 27163744
Nutr Rev. 2017 Dec 1;75(12):1059-1080
pubmed: 29190368
Microbiol Spectr. 2017 Sep;5(5):
pubmed: 28936943
Am J Clin Nutr. 2011 May;93(5):1062-72
pubmed: 21389180
Neurogastroenterol Motil. 2017 Sep;29(9):
pubmed: 28418214
Curr Oncol Rep. 2016 Jul;18(7):45
pubmed: 27255389
Nat Rev Endocrinol. 2019 Dec;15(12):701-712
pubmed: 31616073
Commun Biol. 2018 Dec 7;1:222
pubmed: 30534614
Nutrients. 2015 Mar 31;7(4):2237-60
pubmed: 25835047
Microbiome. 2020 Aug 19;8(1):118
pubmed: 32814582
Appetite. 2005 Feb;44(1):1-13
pubmed: 15604029
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Metabolism. 2017 Mar;68:133-144
pubmed: 28183445
Metabolism. 2004 Dec;53(12):1522-6
pubmed: 15562393
Nutrients. 2017 Jan 29;9(2):
pubmed: 28146065
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
FEMS Microbiol Ecol. 2019 Jan 1;95(1):
pubmed: 30304332
Pharmacol Res. 2020 Sep;159:104985
pubmed: 32504839
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Diabet Med. 1994 Apr;11(3):286-92
pubmed: 8033528
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Int J Body Compos Res. 2008;6(4):173-184
pubmed: 21643542
Nutrients. 2018 Feb 28;10(3):
pubmed: 29495569
Benef Microbes. 2020 Sep 1;11(5):411-455
pubmed: 32865024
Nature. 2011 May 12;473(7346):174-80
pubmed: 21508958
Adv Nutr. 2020 Mar 1;11(2):420-438
pubmed: 31342059
J Agric Food Chem. 2018 Jun 13;66(23):5821-5831
pubmed: 29701959
J Lipid Res. 2014 May;55(5):978-90
pubmed: 24627129
Cell Metab. 2014 Dec 2;20(6):953-66
pubmed: 25456737
Nature. 2016 Jul 21;535(7612):376-81
pubmed: 27409811
Am J Prev Med. 2018 Oct;55(4):565-574
pubmed: 30126667
Gut. 2010 Dec;59(12):1589-90
pubmed: 20940281
Pediatrics. 2017 Jul;140(1):
pubmed: 28759403
J Diabetes Sci Technol. 2015 Jul;9(4):808-14
pubmed: 25802471
Crit Rev Food Sci Nutr. 2009 Apr;49(4):327-60
pubmed: 19234944
Endocrine. 2009 Aug;36(1):141-6
pubmed: 19387874
J Pediatr. 2010 Feb;156(2):247-52.e1
pubmed: 19863969
Int J Obes (Lond). 2019 Jan;43(1):149-157
pubmed: 29777234
World J Pediatr. 2019 Aug;15(4):315-321
pubmed: 31077083
EBioMedicine. 2015 Jul 10;2(8):968-84
pubmed: 26425705
Protein Cell. 2018 May;9(5):397-403
pubmed: 29725936
Pediatr Res. 2015 Dec;78(6):723-9
pubmed: 26331767
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71
pubmed: 23671105
Med Sci Sports Exerc. 1995 Dec;27(12):1692-7
pubmed: 8614327
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Science. 2018 Mar 9;359(6380):1151-1156
pubmed: 29590046
CMAJ. 2018 Sep 17;190(37):E1097-E1107
pubmed: 30224442